Building on more than three decades of legacy in oncology, our commitment to pioneering new advances and transforming outcomes for patients has never been stronger. Our ambition is to be in front of cancer. #ESMO24 #InFrontofCancer
About us
At Johnson & Johnson Innovative Medicine, we are leading where medicine is going. The experiences of patients around the world inform and inspire our science-based innovations, which continue to change and save lives. Applying rigorous science with compassion, we confidently address the most complex diseases of our time and develop the potential medicines of tomorrow. We are continuously working to develop treatments, aspiring to find cures, pioneering the path from lab to life, and championing patients every step of the way. Visit our Johnson & Johnson Innovative Medicine EMEA website here: https://www.janssen.com/emea
- Website
-
https://www.janssen.com/emea/?utm_source=linkedin&utm_medium=organic&utm_campaign=bio
External link for J&J Innovative Medicine Europe, Middle East & Africa (EMEA)
- Industry
- Pharmaceutical Manufacturing
- Company size
- 10,001+ employees
- Headquarters
- Beerse
- Type
- Public Company
Locations
-
Primary
Turnhoutseweg, 30
Beerse, BE
Employees at J&J Innovative Medicine Europe, Middle East & Africa (EMEA)
Updates
-
On your marks, get set, go! Cycling for Children starts today! Wishing all our participants and volunteers a successful event in their local regions. #CyclingforChildren2024 #CyclingforSmiles
-
Today, the ESMO - European Society for Medical Oncology (ESMO) Congress kicks off in Barcelona! We’re excited to witness the innovations and advancements that will take centre stage. Before diving into the latest insights from the congress, why not test your knowledge about bladder cancer?
This content isn’t available here
Access this content and more in the LinkedIn app
-
The right cancer treatment starts with the right testing. Biomarker testing plays a key role in identifying targeted interventions that are likely to benefit specific patients based upon their unique features and disease characteristics. In an article published within The Pathologist, Ales Ryska, Chair, Department of Pathology, Charles University Medical Faculty, Hradec Králové, Czech Republic, shares his vision about how collectively, we can optimise the multidisciplinary approach to enhance biomarker testing and transform patient outcomes in oncology. Multidisciplinary collaboration is the key to optimising biomarker testing and access to precision medicine in earlier lines of therapy. Let’s work together to shape the future of cancer care. Read more here: https://brnw.ch/21wMvJ5 #Pathology #PrecisionMedicine #BiomarkerTesting
-
B-cell malignancies can come in various forms, each with unique characteristics and treatment approaches. Mantle cell lymphoma (MCL) is a rare and aggressive type, often diagnosed at an advanced stage. Increasing our understanding of complex blood cancers like MCL is crucial to transform outcomes and better meet individual patient needs. This Blood Cancer Awareness Month, watch to learn more about MCL. #MantleCellLymphoma #BloodCancerAwarenessMonth #Lymphoma
-
At J&J, we understand the profound impact of precision medicine on cancer care and are excited to engage with experts on the latest advancements in pathology and targeted therapies at the European Society of Pathology’s European Congress of Pathology. Today’s cancer diagnosis goes beyond tumour origin and stage – it needs complementary molecular profiling. Biomarker testing is crucial for selecting the best treatments and identifying patients who will best respond to targeted therapies. But this is only possible through collaboration. A new article published in The Pathologist with insights from Ales Ryska, Chair, Department of Pathology, Charles University Medical Faculty, Hradec Králové, Czech Republic, explores how collectively, we can optimise biomarker testing to revolutionise cancer care, starting with the pathologist. Read more to see how we can shape the future of oncology together: https://lnkd.in/eQS5N5_G #Pathology #PrecisionMedicine #ESPCongress
-
We’re in San Diego for the World Conference on Lung Cancer (WCLC) 2024! Join us in exploring the latest cutting-edge developments that are shaping and revolutionising the treatment landscape for patients with lung cancer. It’s moments like this that drive our ambition to get in front of cancer. Here’s to a remarkable conference packed with inspiration, learning, and opportunities to connect with peers. #WCLC2024 #LungCancer #InFrontofCancer
-
Due to the non-specific signs of leukaemia, it can be difficult to spot, leading to delays in diagnosis. Key symptoms may include fatigue, fever, repeated infections, bruising or bleeding and joint pain. This World Leukaemia Day we are standing with Acute Leukemia Advocates Network (ALAN) to help raise awareness of leukaemia. By working together to increase awareness of the signs and symptoms of leukaemia, we can help foster earlier diagnoses and improve outcomes for people who live with leukaemia. #WLD24 #BeLeukemiaAware #Leukemia #BloodCancerAwarenessMonth
-
One week to go until we’re at the starting line for #CyclingforChildren2024 in support of Operation Smile! We’re proud that we’re working together to improve the health and lives of children with cleft conditions.
-
We’re headed to Barcelona, Spain for ESMO - European Society for Medical Oncology 2024 Conference on September 13th - September 17th and you’re invited to be part of it! Meet us at booth 610 and connect with our oncology, medical affairs, market access, R&D leaders and recruiting team, to learn how your skills can solve the world’s toughest health challenges at Johnson & Johnson. Register to our talent hub here https://lnkd.in/exSWN9Fq Eline De Nys, Gert Quintiens, Iva Yanakieva, Amanda Waldowski, Dan Kollock CDR, CIR, Miles D. Freeman, Matt Houseman, Michael Coyle, David Cretone, Ícaro Taynan (him/his)